Study on segmented-rotor switched reluctance motors with different rotor pole numbers for bsg system of hybrid electric vehicles

© 1967-2012 IEEE. This paper investigates the design principles and performance optimization for segmented-rotor switched reluctance motors (SRSRMs) with different rotor pole numbers for belt-driven starter generators of hybrid electric vehicles. For the design principles, several constraints are derived for the numbers of stator and rotor poles, the dimensions, and the number of winding turns. Two SRSRMs with 16/10 and 16/14 stator/rotor poles are presented according to these principles. For the performance optimization, the two motors are optimized individually for maximizing the torque. To evaluate the effect of different segmented-rotor numbers, the overall performances of the two SRSRMs are investigated and compared. It is found that the 16/14 SRSRM has higher flux linkage and static torque. The 16/14 SRSRM exhibits higher torque and lower torque ripple at low speed operation, whereas at high speed, the 16/10 SRSRM performs better in terms of torque and power densities. Compared with the 16/14 SRSRM, the 16/10 SRSRM has higher final steady speed under the same startup condition. The 16/10 SRSRM can achieve higher steady speed under starter mode and provide higher generated power under braking mode. Moreover, the 16/10 SRSRM exhibits higher efficiency in the most feasible speed range, especially in high speed range, and it has wider high-efficiency area. Finally, a 16/10 SRSRM is prototyped and tested to validate the simulation results

Modified yupingfeng formula for the treatment of stable chronic obstructive pulmonary disease: a systematic review of randomized controlled trials

Background: Chronic obstructive pulmonary disease (COPD), is a very  common disease of respiratory system. An increasing number of clinical  trials on Yupingfeng formula in the management of stable COPD have been performed. However, the evidence base for it remains unknown. This review aims at assessing the efficacy, and safety of modified Yupingfeng  formula in the treatment of stable COPD through a systematic review of all available randomized controlled trials. Materials and Methods: Literature retrieval was conducted using four English databases (CENTRAL, PubMed, EMBASE, and ISI Web of Science), and four Chinese databases (CBM, CNKI, VIP, and WANFANG), from respective inception to January 2013, and supplemented with a manual search. Review authors independently extracted the trial data, and assessed the quality of each trial. Methodological quality was assessed by Cochrane risk of bias and Jadad’s scale. The following outcomes were evaluated: (1) lung function; (2) 6-minute walk distance (6MWD); (3) effective rate; (4) serum levels of IgA, IgG and IgE; and (5) adverse events. Data were analyzed using STATA 12.0 software.Results: A total of nine studies involving 660, stable COPD patients were identified. Patients from all studies included in this review were randomized to receive Yupingfeng formula combined with Western medications in comparison with Western medications. In general, the methodological quality of the included trials was poor. The results of this systematic review indicates that, compared with Western medications alone, the use of Yupingfeng formula, if combined with Western medications could significantly improve FEV1 (WMD = 0.30L; 95%CI: 0.19, 0.42), FEV1/FVC ratio (SMD = 0.69; 95%CI: 0.48, 0.91), 6MWD (WMD = 31.73m; 95% CI: 19.29, 44.17), and effective rate (RR = 1.24; 95% CI: 1.10, 1.41), and increase the serum levels of IgA (WMD = 0.25; 95%CI: 0.16, 0.34) and IgG (WMD = 1.10; 95%CI: 0.53, 1.68), but no difference was found in the serum IgE levels (WMD = 0.47; 95%CI: －0.32, 1.27) between the two groups. No serious adverse events were reported.Conclusions: Within the limitations of this systematic review, we may conclude that compared with Western medications alone, Yupingfeng formula, when combined with Western medications can provide more benefits for patients with stable COPD, without any serious adverse reactions being identified. However, these benefits need to be further confirmed through high-quality prospective placebo-controlled trials that should be strictly conducted in accordance with methodological principles and procedures.Key words: Yupingfeng formula; chronic obstructive pulmonary disease; Systematic revie

Agriculture and trade liberalization in the MENA region: Dynamic impacts of future scenarios

[No abstract available

Measurements of branching fractions for inclusive K0~/K0 and K*(892)+- decays of neutral and charged D mesons

Using the data sample of about 33 pb-1 collected at and around 3.773 GeV with the BES-II detector at the BEPC collider, we have studied inclusive K0~/K0 and K*(892)+- decays of D0 and D+ mesons. The branching fractions for the inclusive K0~/K0 and K*(892)- decays are measured to be BF(D0 to K0~/K0 X)=(47.6+-4.8+-3.0)%, BF(D+ to K0~/K0 X)=(60.5+-5.5+-3.3)%, BF(D0 to K*- X)=(15.3+- 8.3+- 1.9)% and BF(D+ to K*- X)=(5.7+- 5.2+- 0.7)%. The upper limits of the branching fractions for the inclusive K*(892)+ decays are set to be BF(D0 to K*+ X)<3.6% and BF(D+ to K*+ X) <20.3% at 90% confidence level

Direct Measurements of the Branching Fractions for Inclusive K±K^\pm and Inclusive Semileptonic Decays of D+D^+ and D0D^0 Mesons

With singly-tagged $\bar D$ samples selected from the data collected at and around 3.773 GeV with the BESII detector at the BEPC collider, we have measured the branching fractions for the inclusive $K^\pm$ decays of $D^+$ and $D^0$ mesons, which are $BF(D^+\to K^-X) = (24.7 \pm 1.3 \pm 1.2)$, $BF(D^+\to K^+X) = (6.1 \pm 0.9 \pm 0.4)$, $BF(D^0\to K^-X) = (57.8 \pm 1.6 \pm 3.2)$ and $BF(D^0\to K^+X) = (3.5 \pm 0.7 \pm 0.3)$, respectively. We have also measured the branching fractions for the inclusive semileptonic decays of $D^+$ and $D^0$ mesons to be $BF(D^+ \to e^+ X)=(15.2 \pm 0.9 \pm 0.8)$ and $BF(D^0 \to e^+ X) =(6.3 \pm 0.7 \pm 0.4)$. These yield the ratio of their partial widths to be $\Gamma(D^+ \to e^+X)/\Gamma(D^0 \to e^+X)=0.95 \pm 0.12 \pm 0.07$.Comment: 6 pages, 5 figure

Efficient methods for signal detection from correlated adverse events in clinical trials

It is an important and yet challenging task to identify true signals from many adverse events that may be reported during the course of a clinical trial. One unique feature of drug safety data from clinical trials, unlike data from post-marketing spontaneous reporting, is that many types of adverse events are reported by only very few patients leading to rare events. Due to the limited study size, the p-values of testing whether the rate is higher in the treatment group across all types of adverse events are in general not uniformly distributed under the null hypothesis that there is no difference between the treatment group and the placebo group. A consequence is that typically fewer than (Formula presented.) percent of the hypotheses are rejected under the null at the nominal significance level of (Formula presented.). The other challenge is multiplicity control. Adverse events from the same body system may be correlated. There may also be correlations between adverse events from different body systems. To tackle these challenging issues, we develop Monte-Carlo-based methods for the signal identification from patient-reported adverse events in clinical trials. The proposed methodologies account for the rare events and arbitrary correlation structures among adverse events within and/or between body systems. Extensive simulation studies demonstrate that the proposed method can accurately control the family-wise error rate and is more powerful than existing methods under many practical situations. Application to two real examples is provided

Measurement of \psip Radiative Decays

Using 14 million psi(2S) events accumulated at the BESII detector, we report first measurements of branching fractions or upper limits for psi(2S) decays into gamma ppbar, gamma 2(pi^+pi^-), gamma K_s K^-pi^++c.c., gamma K^+ K^- pi^+pi^-, gamma K^{*0} K^- pi^+ +c.c., gamma K^{*0}\bar K^{*0}, gamma pi^+pi^- p pbar, gamma 2(K^+K^-), gamma 3(pi^+pi^-), and gamma 2(pi^+pi^-)K^+K^- with the invariant mass of hadrons below 2.9GeV/c^2. We also report branching fractions of psi(2S) decays into 2(pi^+pi^-) pi^0, omega pi^+pi^-, omega f_2(1270), b_1^\pm pi^\mp, and pi^0 2(pi^+pi^-) K^+K^-.Comment: 5 pages, 4 figure

Measurements of J/ψJ/\psi and ψ(2S)\psi(2S) decays into ΛΛˉπ0\Lambda \bar{\Lambda}\pi^0 and ΛΛˉη\Lambda \bar{\Lambda}\eta

Using 58 million $J/\psi$ and 14 million $\psi(2S)$ events collected by the BESII detector at the BEPC, branching fractions or upper limits for the decays $J/\psi$ and $\psi(2S) \to \Lambda \bar{\Lambda}\pi^0$ and $\Lambda \bar{\Lambda}\eta$ are measured. For the isospin violating decays, the upper limits are determined to be ${\cal B}(J/\psi \to \Lambda \bar{\Lambda}\pi^0)<6.4\times 10^{-5}$ and ${\cal B}(\psi(2S) \to \Lambda \bar{\Lambda}\pi^0)<4.9\times 10^{-5}$ at the 90% confidence level. The isospin conserving process $J/\psi \to \Lambda \bar{\Lambda}\eta$ is observed for the first time, and its branching fraction is measured to be ${\cal B}(J/\psi \to \Lambda \bar{\Lambda}\eta)=(2.62\pm 0.60\pm 0.44)\times 10^{-4}$, where the first error is statistical and the second one is systematic. No $\Lambda \bar{\Lambda}\eta$ signal is observed in $\psi(2S)$ decays, and ${\cal B}(\psi(2S) \to \Lambda \bar{\Lambda}\eta)<1.2\times 10^{-4}$ is set at the 90% confidence level. Branching fractions of $J/\psi$ decays into $\Sigma^+ \pi^- bar{\Lambda}$ and $\bar{\Sigma}^- \pi^+ \Lambda$ are also reported, and the sum of these branching fractions is determined to be ${\cal B}(J/\psi \to \Sigma^+\pi^- \bar{\Lambda} + c.c.)=(1.52\pm 0.08\pm 0.16)\times 10^{-3}$.Comment: 7 pages, 10 figures. Phys.Rev.D comments considere

Protective antitumor activity induced by a fusion vaccine with murine beta-defensin2 and VE-cadherin in mouse models

Targeting angiogenesis is an effective strategy for anticancer therapy. The vascular endothelialcadherin (VE-cad) regulated angiogenesis is a potential target for anti-angiogenesis. Here, we develop a fusion vaccine plasmid DNA pSec-MBD2-VE-cad from VE-cad and murine beta defensin2 (MBD2) to induce immunity for cancer therapy. The expression and biological activity of fusion protein were detected in vitro. Anti-tumor effects and inhibition of angiogenesis via pSec-MBD2-VE-cad were investigated in mice model. The anti-VE-cad antibodies and cytotoxic T lymphocyte (CTL) responses were analyzed. Inhibition of tumor-induced angiogenesis and prolonged survival were shown in mice challenged with murine colon adenocarcinoma (CT26) or Murine fibrosarcoma cell line (MethA) after immunization with the fusion vaccine. Moreover, VE-cad-specific antibodies and specific T cell cytotoxicity were detected. The fusion vaccine based on self immune peptide Murine beta defensin2 (MBD2) and self antigen mVE-cad could induce autoimmunity and inhibit tumor growth, and thus there may be potential applications in cancer therapy